Last mentioned: Mar 19, 2026
Q4 2025 Earnings
Both companies report year-end results showing strong commercial momentum and narrowing losses.
Major Health Plan Contract
DarioHealth signs a multi-year agreement with a top-five national US health insurer.
Biofrontera Supply Chain Update
Resolution of RhodoLED manufacturing bottlenecks, enabling faster lamp deployment.
DarioHealth MSK Launch
Full integration of musculoskeletal health modules into the core digital platform.
Biofrontera and DarioHealth reported Q4 2025 earnings, highlighting a pivotal transition from clinical development to aggressive commercial scaling. While Biofrontera capitalizes on its dermatology market share with Ameluz, DarioHealth is demonstrating the viability of its multi-condition digital health platform through expanded B2B partnerships.
Biofrontera Inc. (BFRI) has achieved record financial results for the fourth quarter and full year 2025, signaling a significant shift in the dermatology market toward photodynamic therapy. The company's performance reflects robust adoption of its flagship product, Ameluz, and its proprietary RhodoLED lamp technology in the United States.